Literature DB >> 31932136

Mucosal delivery of live Lactococcus lactis expressing functionally active JlpA antigen induces potent local immune response and prevent enteric colonization of Campylobacter jejuni in chickens.

Chandan Gorain1, Ankita Singh1, Sudipta Bhattacharyya1, Anirban Kundu1, Aritraa Lahiri1, Subhadeep Gupta1, Amirul I Mallick2.   

Abstract

Successful colonization of the mucosal epithelial cells is the key early step for Campylobacter jejuni (C. jejuni) pathogenesis in humans. A set of Surface Exposed Colonization Proteins (SECPs) are known to take leading role in bacterial adhesion and subsequent host pathogenesis. Among the major SECPs, the constitutively expressed C. jejuni surface lipoprotein Jejuni lipoprotein A (JlpA), interacts with intestinal heat shock protein 90α (Hsp90α) and contributes in disease progression by triggering pro-inflammatory responses via activation of NF-κB and p38 MAP kinase pathways. In addition to its ability to express on the surface, high sequence conservation of JlpA protein among different Campylobacter spp make it a suitable vaccine target against C. jejuni. Given that chickens are the primary source for C. jejuni infection in humans and persistent cecal colonization significantly contribute in pathogen transmission, we explicitly used chickens as a model to test the immune-protective efficacy of JlpA protein. Taking into account that gastro-intestinal tract is the major site for C. jejuni colonization, we chose to use mucosal (intragastric) route as mode for JlpA antigen delivery. To deliver JlpA via mucosal route, we engineered a food grade Lactic acid producing bacteria, Lactococcus lactis (L. lactis) to express functionally active JlpA protein in the surface. Further, we demonstrated its ability to substantially improve the antigen specific local immune responses in the intestine along with significant immune-protection against enteric colonization of C. jejuni in chickens.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Campylobacter jejuni; Enteric colonization; JlpA; Lactococcus lactis; Mucosal immune response

Mesh:

Substances:

Year:  2020        PMID: 31932136     DOI: 10.1016/j.vaccine.2019.12.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Identification of Novel Bioactive Compound Derived from Rheum officinalis against Campylobacter jejuni NCTC11168.

Authors:  Mohammed Yosri; Basma H Amin; Nermine N Abed; Amal S Elithy; Sayed M Kareem; Nagwa M Sidkey
Journal:  ScientificWorldJournal       Date:  2020-07-01

Review 2.  Plasmid Replicons for the Production of Pharmaceutical-Grade pDNA, Proteins and Antigens by Lactococcus lactis Cell Factories.

Authors:  Sofia O D Duarte; Gabriel A Monteiro
Journal:  Int J Mol Sci       Date:  2021-01-30       Impact factor: 5.923

Review 3.  Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development.

Authors:  Zhulin Jiang; Shuihong Li; Cuiming Zhu; Runjie Zhou; Polly H M Leung
Journal:  Pathogens       Date:  2021-01-25

Review 4.  Campylobacter Virulence Factors and Molecular Host-Pathogen Interactions.

Authors:  Nicole Tegtmeyer; Irshad Sharafutdinov; Aileen Harrer; Delara Soltan Esmaeili; Bodo Linz; Steffen Backert
Journal:  Curr Top Microbiol Immunol       Date:  2021       Impact factor: 4.291

5.  Bioengineering of LAB vector expressing Haemolysin co-regulated protein (Hcp): a strategic approach to control gut colonization of Campylobacter jejuni in a murine model.

Authors:  Chandan Gorain; Afruja Khan; Ankita Singh; Samiran Mondal; Amirul Islam Mallick
Journal:  Gut Pathog       Date:  2021-07-30       Impact factor: 4.181

6.  Lactococcus lactis Expressing Type I Interferon From Atlantic Salmon Enhances the Innate Antiviral Immune Response In Vivo and In Vitro.

Authors:  Carlos Muñoz; Josue González-Lorca; Mick Parra; Sarita Soto; Natalia Valdes; Ana María Sandino; Rodrigo Vargas; Alex González; Mario Tello
Journal:  Front Immunol       Date:  2021-08-12       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.